Clover Health Investments
Clover Health Investments' revenue rose 40.3% to $1.9 billion in fiscal 2025. Its operating margin was −4.4%, down from −3.3% a year earlier. Free cash flow was −$69 million, against $33 million a year earlier. It paid out $18 million in dividends and buybacks. The diluted share count rose 4.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Clover Health Investments does
Clover Health is a Medicare Advantage insurer, which means it offers health plans to older Americans through the government's Medicare program, and it also sells software. Its software platform, Clover Assistant, is licensed to outside customers as Counterpart Assistant. It gives doctors data and suggestions at the point of care to help find and manage chronic diseases earlier.
It earns money mainly from the premiums for its Medicare Advantage plans and pays the medical costs of its members. It also hopes to earn software fees by providing the platform to other insurers and physician groups. The software combines data from over 100 sources. Clover says it measures how much of premiums go to medical costs with a benefits expense ratio, a non-GAAP measure.
It builds networks of physicians, and its members are concentrated in certain geographic areas.
Its biggest risks, as it describes them
- It has lost money in the past and may not become or stay profitable.
- Doctors may use Clover Assistant less than it expects, which would slow growth.
- It may misjudge, price for or manage members' medical costs.
- Government risk adjustment payments make its revenue hard to predict and can be adjusted back in time.
- Its members are concentrated in certain areas, exposing it to local cost and competition changes.
Income statement
Clover Health Investments lost money in fiscal 2025: a net loss of $86 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 321 | 293 | 224 | 222 | 101 |
| Debt incl. finance leases | 20 | 0 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −301 | −293 | −224 | −222 | −101 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −199.5x | −215.1x | −29,332.7x | — | — |
| Current ratio | 2.0x | 1.4x | 1.6x | 1.6x | 1.5x |
| Quick ratio | 2.0x | 1.4x | 1.6x | 1.6x | 1.5x |
Cash flow
Projections
Project Clover Health Investments' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Clover Health Investments shares on the open market, and 8 insiders sold $6.6 million, $5.6 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | Jamie L. ReynosoCEO, Medicare Advantage | Sold plan | 1,921 | $4.56 | $8,760 | Form 4 |
| Sep 16, 2026 | Joseph Frank OldakowskiVP of Finance and Controller | Sold plan | 3,170 | $4.64 | $14,709 | Form 4 |
| Sep 15, 2026 | Conrad WaiCEO, Counterpart Health | Sold plan | 300,000 | $4.72 | $1.4 million | Form 4 |
| Sep 15, 2026 | Jamie L. ReynosoCEO, Medicare Advantage | Sold plan | 9,273 | $4.78 | $44,325 | Form 4 |
| Sep 15, 2026 | Karen SoaresChief Legal Officer | Sold plan | 6,846 | $4.78 | $32,724 | Form 4 |
| Sep 14, 2026 | Joseph Frank OldakowskiVP of Finance and Controller | Sold | 20,000 | $5.16 | $103,200 | Form 4 |
| Aug 17, 2026 | Joseph Clay ThorntonInterim CFO | Sold plan | 17,775 | $4.39 | $78,032 | Form 4 |
| Aug 10, 2026 | Andrew ToyChief Executive Officer, Director | Sold plan | 87,798 | $4.65 | $408,261 | Form 4 |
| Jul 20, 2026 | Karen SoaresChief Legal Officer | Sold plan | 51,700 | $4.51 | $233,167 | Form 4 |
| Jul 17, 2026 | Jamie L. ReynosoCEO, Medicare Advantage | Sold plan | 4,839 | $4.53 | $21,921 | Form 4 |
| Jul 15, 2026 | Andrew ToyChief Executive Officer, Director | Sold plan | 62,711 | $4.67 | $292,860 | Form 4 |
| Jul 15, 2026 | Conrad WaiCEO, Counterpart Health | Sold plan | 24,215 | $4.67 | $113,084 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 4 of 8 | 2 of 8 |
| Rule of 40 | 3.4% | 11.2% | 36.8% |
| Altman Z'' | −11.78 | −9.94 | −12.26 |
| Accruals ratio | −10.0% | −13.5% | −3.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Fail |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | — | — |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 5 of 9 | 4 of 8 | 2 of 8 |
Compare
Put Clover Health Investments side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Clover Health Investments | FY25 | 40.3% | −4.4% | −3.6% | −41.3% | — | 2 | |
| HealthEquity | FY26 | 9.5% | 24.6% | 34.6% | 8.9% | 1.3x | 9 | Compare |
| Oscar Health | FY25 | 27.5% | −3.4% | 9.1% | — | — | 4 | Compare |
| Molina Healthcare | FY25 | 11.8% | 1.7% | −1.4% | — | −4.4x | 4 | Compare |
| Humana | FY25 | 10.1% | 2.1% | 0.3% | 25.7% | −2.2x | 5 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 462 | 673 | 1,472 | 1,097 | 1,260 | 1,371 | 1,924 |
| Revenue growth | — | 45.6% | 118.8% | −25.5% | 15.0% | 8.8% | 40.3% |
| Gross profit | — | — | −79 | 23 | 257 | — | — |
| Research and development | — | — | — | — | — | — | — |
| Operating income | −183 | −93 | −637 | −287 | −205 | −46 | −86 |
| Net income | −364 | −136 | −588 | −340 | −213 | −43 | −86 |
| Diluted EPS (US$) | −4.14 | −1.54 | −1.42 | −0.71 | −0.44 | −0.09 | −0.17 |
| Diluted shares (millions) | 88 | 89 | 413 | 476 | 482 | 490 | 512 |
| Cash flow | |||||||
| Cash from operations | −160 | −118 | −282 | −204 | −145 | 35 | −67 |
| Capital expenditure | 0 | 1 | 1 | 4 | 1 | 2 | 2 |
| Free cash flow | −160 | −119 | −283 | −208 | −145 | 33 | −69 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 2 | 18 |
| Acquisitions | 1 | 0 | 0 | 16 | 0 | 0 | 0 |
| Stock-based compensation | 3 | 7 | 164 | 164 | 141 | 114 | 104 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 0 | 92 | 321 | 293 | 224 | 222 | 101 |
| Debt incl. finance leases | — | 127 | 20 | 0 | 0 | 0 | 0 |
| Total assets | 0 | 267 | 951 | 809 | 571 | 581 | 541 |
| Total liabilities | 0 | 433 | 411 | 452 | 284 | 240 | 232 |
| Shareholders' equity | −0 | −617 | 535 | 348 | 286 | 341 | 309 |
| Margins and ratios | |||||||
| Gross margin | — | — | −5.4% | 2.1% | 20.4% | — | — |
| Operating margin | −39.6% | −13.8% | −43.3% | −26.1% | −16.3% | −3.3% | −4.4% |
| Net margin | −78.7% | −20.3% | −39.9% | −31.0% | −16.9% | −3.1% | −4.5% |
| Free cash flow margin | −34.6% | −17.7% | −19.2% | −19.0% | −11.5% | 2.4% | −3.6% |
| Rule of 40 (growth + FCF margin) | — | 27.9% | 99.5% | −44.5% | 3.4% | 11.2% | 36.8% |
| Return on capital | — | — | — | −149.7% | — | −39.6% | −41.3% |
| Return on equity | — | — | — | −76.9% | −67.3% | −13.7% | −26.3% |
| Return on assets | — | −102.0% | −96.5% | −38.6% | −30.9% | −7.5% | −15.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — |